Journal article
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance
An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA—TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national prevention campaign, vaccinating 11·4 million people aged 1—29 years. The researchers analysed national surveillance data around PsA—TT introduction to investigate the early effect of the vaccine on meningitis incidence and epidemics.
Authors
Languages
- English
Publication year
2012
Journal
The Lancet Infectious Diseases
Volume
10
Type
Journal article
Categories
- Service delivery
Diseases
- Meningococcal meningitis
Countries
- Burkina Faso
Tags
- Coverage monitoring
- New vaccine introduction
WHO Regions
- African Region
